Randi J. Hagerman, M.D.

Clinical Interests
Randi J. Hagerman has more than 20 years of experience in the field of neurodevelopmental disorders and fragile X syndrome — the most common inherited cause of mental retardation. Her research focuses on the correlation between an individual's molecular genotype, or genetic make-up, and physical and behavioral characteristics, in addition to targeted treatments for Fragile X Syndrome and the fragile X-associated tremor ataxia syndrome (FXTAS). She also has a strong clinical and research interest in autism and has conducted research examining the association between autism and fragile X syndrome. Her books include *Neurodevelopmental Disorders: Diagnosis and Treatment,* published by Oxford University Press in 1999, and *Fragile X Syndrome: Diagnosis, Treatment, and Research,* published by Johns Hopkins in 2002.

Title
Medical Director, UC Davis MIND Institute
Professor and Endowed Chair in Fragile X Research

Specialty
Pediatric Child Development & Behavior

Department
Pediatrics

Division
Child Development and Behavior

Center/Program Affiliation
UC Davis Children's Hospital
UC Davis MIND Institute

Address/Phone
UC Davis MIND Institute, 2825 50th St. Sacramento, CA 95817
Phone: 916-703-0280

Additional Phone
Phone: 916-703-0257
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Languages
Spanish

Education
M.D., F.A.A.P., Stanford University School of Medicine, Palo Alto, California, 1975
B.S., UC Davis, Davis, California, 1971

Internships
Stanford University School of Medicine, Palo Alto, California, 1975-76

Residency
Stanford University School of Medicine, Palo Alto, California, 1976-77
University of California, San Diego, La Jolla, California, 1979-80

Fellowships
University of California, San Diego, La Jolla, California, 1978-80

UCDAVIS HEALTH SYSTEM

Randi J. Hagerman, M.D.

Professional Memberships

American Academy of Pediatrics
American Society of Human Genetics
Society of Developmental and Behavioral Pediatrics

Select Recent Publications

Greco CM, Navarro CS, Hunsaker MR, Maezawa I, Shuler JF, Tassone F, Delany M, Au JW, Berman RF, Jin LW, Schumann C, Hagerman PJ and Hagerman RJ Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol Autism 2011 Feb 8; 2(1):2. doi:10.1186/2040-2392-2-2 PMC3045897

Hashimoto R, Backer KC, Tassone F, Hagerman RJ, Rivera SM. (2011) An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). J Psychiatr Res 2011;45(1)36-43.

Hashimoto R, Javan AK, Tassone F, Hagerman RJ, Rivera SM. (2011) A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome. Brain Mar 2011:134(Pt. 3):863-78.

Hashimoto R, Javan AK, Tassone F, Hagerman RJ, Rivera SM. A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome. BRAIN 2011 134(Pt 3):863-878.

Hashimoto RI, Srivastava S, Tassone F, Hagerman RJ, Rivera SM. Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene. Mov Disord Apr 2011, doi: 10.1002 /mds.23646 [Epub ahead of print] PMID: 21484870.

Narcisa V, Aguilar D, Nguyen DV, Campos L, Brodovsky J, White S, Adams P, Tassone F, Hagerman PJ, Hagerman RJ. A Quantitative Assessment of Tremor and Ataxia in Female FMR1 Premutation Carriers using CATSYS. Current Gerentology and Geriatrics Research doi:10.1155 /2011/484713.

Stöger R, Genereux DP, Hagerman RJ, Hagerman PJ, Tassone F, Laird CD. Testing the FMR1 Promoter for Mosaicism in DNA Methylation among CpG Sites, Strands, and Cells in FMR1-Expressing Males with Fragile X Syndrome. PLoS ONE:6(8):E23648. EPub 2011 Aug 31.

Zhang L, Sukharev D, Schneider A, Olichney JM, Seritan A, Hagerman RJ. Case report: Dystonia in a fragile X carrier. Mov Disord 2011 (Epub ahead of print].

Ortigas MC, Bourgeois JA, Schneider A, Olichney J, Nguyen DV, Cogswell JB, Hall DA, Hagerman RJ. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol 2010;30(5):642-4.

Paul R, Pessah IN, Gane L, Ono M, Hagerman PJ, Brunberg JA, Tassone F, Bourgeois JA, Adams PE, Nguyen DV, Hagerman R. Early onset of neurological symptoms in fragile X premutation

Randi J. Hagerman, M.D.

carriers exposed to neurotoxins. NeuroToxicology 2010;31:399-402.
Schneider A, Ballinger E, Chavez A, Tassone F, Hagerman RJ, Hessl D. Prepulse inhibition in patiens with fragile X-associated tremor/ataxia syndrome. Neurobiol Aging 2010 [Epub ahead of print].
Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet Danielle, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B. Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056. Science Translational Medicine 2010;3(64):64ra1.
Hagerman RJ, Hendren RL. Shifting the paradigm for autism treatments. Neurotherapeutics 2010 Jul:7(3):230-231.

© 2013 UC Regents

UCDAVIS
HEALTH SYSTEM